Personalis Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 260

Employees

  • Stock Symbol
  • PSNL

Stock Symbol

  • Share Price
  • $15.71
  • (As of Friday Closing)

Personalis General Information

Description

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 6600 Dumbarton Circle
  • Fremont, CA 94555
  • United States
+1 (855)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 6600 Dumbarton Circle
  • Fremont, CA 94555
  • United States
+1 (855)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Personalis Stock Performance

As of 13-Nov-2026, Personalis’s stock price is $15.71. Its current market cap is $1.7B with 108M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$15.71 $15.86 $4.96 - $18.89 $1.7B 108M 2.7M -$1.16

Personalis Financials Summary

As of 30-Sep-2026, Personalis has a trailing 12-month revenue of $80.8M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,564,040 597,399 391,031 29,584
Revenue 80,770 69,648 84,614 73,481
EBITDA (116,852) (78,153) (75,811) (102,708)
Net Income (119,328) (81,270) (81,284) (108,296)
Total Assets 291,600 334,164 270,268 225,099
Total Debt 37,200 39,948 44,247 47,728
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Personalis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Personalis‘s full profile, request access.

Request a free trial

Personalis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Personalis‘s full profile, request access.

Request a free trial

Personalis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized ca
Drug Discovery
Fremont, CA
260 As of 2025

Seoul, South Korea
 

Irving, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Personalis Competitors (36)

One of Personalis’s 36 competitors is CJ Bioscience, a Formerly VC-backed company based in Seoul, South Korea.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CJ Bioscience Formerly VC-backed Seoul, South Korea
Caris Life Sciences Formerly PE-Backed Irving, TX
Inotiv Formerly PE-Backed West Lafayette, IN
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Champions Oncology Formerly VC-backed Hackensack, NJ
You’re viewing 5 of 36 competitors. Get the full list »

Personalis Patents

Personalis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12706180-B2 System and method for management of compressed sequencing files Active 27-Jun-2024
US-20260004886-A1 System and method for management of compressed sequencing files Active 27-Jun-2024
US-20260351351-A1 System and method for management of compressed sequencing files Pending 27-Jun-2024
WO-2026006629-A1 System and method for management of compressed sequencing files Pending 27-Jun-2024
EP-4526481-A2 Methods and system for using methylation data for disease detection and quantification Pending 19-May-2022 G16B20/20
To view Personalis’s complete patent history, request access »

Personalis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Personalis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Personalis‘s full profile, request access.

Request a free trial

Personalis ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

25.52 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Personalis’s complete esg history, request access »

Personalis FAQs

  • When was Personalis founded?

    Personalis was founded in 2011.

  • Where is Personalis headquartered?

    Personalis is headquartered in Fremont, CA.

  • What is the size of Personalis?

    Personalis has 260 total employees.

  • What industry is Personalis in?

    Personalis’s primary industry is Drug Discovery.

  • Is Personalis a private or public company?

    Personalis is a Public company.

  • What is Personalis’s stock symbol?

    The ticker symbol for Personalis is PSNL.

  • What is the current stock price of Personalis?

    As of 13-Nov-2026 the stock price of Personalis is $15.71.

  • What is the current market cap of Personalis?

    The current market capitalization of Personalis is $1.7B.

  • What is Personalis’s current revenue?

    The trailing twelve month revenue for Personalis is $80.8M.

  • Who are Personalis’s competitors?

    CJ Bioscience, Caris Life Sciences, Inotiv, Sangamo Therapeutics, and Champions Oncology are some of the 36 competitors of Personalis.

  • What is Personalis’s annual earnings per share (EPS)?

    Personalis’s EPS for 12 months was -$1.16.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process